April 15 (Reuters) – The U.S. Food and Drug Administration
has rejected Chiasma Inc’s experimental drug to treat
adults with a type of growth disorder, the company said on
Friday.
The post UPDATE 1-U.S. FDA rejects Chiasma’s drug to treat growth disorder appeared first on NASDAQ.